Holen Sie sich die Stockscreener-App
95.60
1.45%
1.37
Handel nachbörslich:
95.64
0.04
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$94.23
Offen:
$94.65
24-Stunden-Volumen:
6.55M
Relative Volume:
1.07
Marktkapitalisierung:
$296.41B
Einnahmen:
$58.07B
Nettoeinkommen (Verlust:
$9.40B
KGV:
31.75
EPS:
3.0113
Netto-Cashflow:
$9.87B
1W Leistung:
+6.29%
1M Leistung:
+2.91%
6M Leistung:
+31.57%
1J Leistung:
+36.42%
1-Tages-Spanne:
$94.65
$96.18
1-Wochen-Bereich:
$89.04
$96.18
52-Wochen-Spanne:
$61.24
$96.51
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
95.60 | 292.17B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca PLC ADR Outperforms Competitors On Strong Trading Day - 富途牛牛
AstraZeneca (LON:AZN) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Citi initiates coverage of European pharma stocks; AstraZeneca ‘best in class’ - Investing.com Nigeria
Citi initiates coverage of European pharma stocks; AstraZeneca ‘best in class’ By Investing.com - Investing.com South Africa
Broker tips: Zotefoams, Burberry, AstraZeneca, GSK - Sharecast.com
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK - Sharecast.com
AstraZeneca the 'top pick' among European pharmasbroker - Proactive Investors
Vanguard Personalized Indexing Management LLC Raises Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca and GSK to accompany Keir Starmer to China to strengthen economic cooperation - marketscreener.com
Why Astrazeneca (AZN) Outpaced the Stock Market Today - Yahoo Finance
Decliners Report: Why is AstraZeneca PLC Depositary Receipt stock going upJuly 2025 Gainers & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Drugmakers AstraZeneca, GSK to join Starmer delegation to China, sources say - Reuters
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Y Intercept Hong Kong Ltd Has $5.11 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
Oxbow Advisors LLC Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Jennison Associates LLC Sells 8,481,701 Shares of AstraZeneca PLC $AZN - MarketBeat
Risk Hedge: Is AstraZeneca PLC Depositary Receipt vulnerable to short sellersQuarterly Profit Summary & Accurate Entry/Exit Alerts - baoquankhu1.vn
AstraZeneca (LON:AZN) Shares Cross Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
US court: AstraZeneca, Johnson & Johnson, Pfizer, Roche and other pharmaceutical companies must face allegations of aiding terrorist organizations in Iraq - Bitget
AstraZeneca's Tagrisso® and Calquence® Among First Oncology Treatments Granted Accelerated Access Through Ontario's FAST Program – Company AnnouncementFT.com - Financial Times
AstraZeneca plc: How a Reinvented Pharma Powerhouse Turned Its Pipeline Into a Platform - AD HOC NEWS
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ - Pharmaceutical Technology
AstraZeneca plc Stock Is Quietly Going Off — Is This Your Next Power Move? - AD HOC NEWS
Migdal Insurance & Financial Holdings Ltd. Acquires Shares of 194,000 AstraZeneca PLC $AZN - MarketBeat
Prediction: Analysts think the AstraZeneca share price will do this in 2026 - MSN
Eyes on Asia: AirNexis, AstraZeneca, Syngene International - BioXconomy
AstraZeneca - Britannica
Astrazeneca expands China cell therapy footprint with Abelzeta CAR T - BioWorld MedTech
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates - TechStock²
AstraZeneca to delist from Nasdaq, join NYSE in February - Reuters
Why Is AstraZeneca Stock Trading Lower Today?AstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Shifts Listing from Nasdaq to NYSE - GuruFocus
AstraZeneca to move NYSE listing, withdraw from Nasdaq at end of January - Investing.com
Dynasty Wealth Management LLC Invests $3.27 Million in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to complete direct listing in NY on February 2 - marketscreener.com
AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial - Finviz
AstraZeneca PLC (NASDAQ:AZN) Emerges as a Quality Investment Candidate - Chartmill
AstraZeneca (AZN) to Consolidate Stock Listings on NYSE - GuruFocus
AstraZeneca To Move Nasdaq Listing To NYSE - directorstalkinterviews.com
AstraZeneca Plans NYSE Listing for Shares, US Debt - Mirage News
AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange - AstraZeneca
AstraZeneca (AZN): EMA Considers Enhertu for Breast Cancer Treat - GuruFocus
AstraZeneca share price slips in London as tariff threat rattles markets; EMA review and earnings in focus - TechStock²
AstraZeneca's Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Finviz
AstraZeneca’s Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Yahoo Finance
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy - Yahoo Finance
Prediction: analysts think the AstraZeneca share price will do this in 2026 - Yahoo Finance UK
AbelZeta and AstraZeneca Reach $630 Million Acquisition Agreement - Intellectia AI
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):